GEOVAX LABS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
GEOVAX LABS, INC. (GOVX) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $3.14 million as of 2026-06-30, per its S-1 filed 2026-09-17.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-09-17
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $3.14M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $1.27M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $3.09M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $5.01M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $3.14M S-1 · filed 2026-09-17 |
| 2026-03-31 | $1.27M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $3.09M S-1 · filed 2026-09-17 |
| 2025-09-30 | $5.01M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $3.09M S-1 · filed 2026-09-17 |
| 2025-03-31 | $7.44M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $5.51M S-1 · filed 2026-09-17 |
| 2024-09-30 | $8.59M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $1.56M 10-Q · filed 2025-07-28 |
| 2024-03-31 | $768.86K 10-Q · filed 2025-05-01 |
| 2023-12-31 | $6.45M S-1 · filed 2026-09-17 |
| 2023-09-30 | $12.69M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $17.79M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $23.85M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $27.61M 10-K · filed 2025-03-27 |
| 2022-09-30 | $34.68M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $30.90M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $16.26M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $11.42M 10-K · filed 2024-02-29 |
| 2021-09-30 | $18.11M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $19.54M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $20.84M 10-Q · filed 2022-04-27 |
| 2020-12-31 | $9.88M 10-K · filed 2023-03-23 |
| 2020-09-30 | $11.58M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $710.68K 10-Q · filed 2021-08-11 |
| 2020-03-31 | $221.81K 10-Q · filed 2021-05-06 |
| 2019-12-31 | $283.34K 10-K · filed 2022-03-09 |
| 2019-09-30 | $569.36K 10-Q · filed 2020-11-05 |
| 2019-06-30 | $216.41K 10-Q · filed 2020-08-10 |
| 2018-12-31 | $259.70K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |